



(51) International Patent Classification:

C07D 413/12 (2006.01) A61K 31/506 (2006.01)
C07D 417/12 (2006.01) A61K 31/4155 (2006.01)
C07D 471/04 (2006.01) A61P 25/04 (2006.01)
C07D 261/20 (2006.01) A61P 3/10 (2006.01)

(21) International Application Number:

PCT/US2014/068359

(22) International Filing Date:

3 December 2014 (03.12.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/919,605 20 December 2013 (20.12.2013) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333
Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors: GRAUPE, Michael; C/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, CA 94404 (US). LU,
Yafan; C/o Gilead Sciences, Inc., 333 Lakeside Drive,
Foster City, CA 94404 (US). ZABLOCKI, Jeff, A.; C/o
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA
94404 (US).

(74) Agents: GINAH, Francis, O. et al.; Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, CA 94404 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS



(I)

(57) Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, Y, Z, R², R³, R⁴, p and q are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.